Delivery compound has multiple uses


Insmed, a biopharmaceutical company located in Virginia’s Biotechnology Research Park, makes a proprietary delivery compound of insulin-like growth factor-I (IGF-I) bound to its primary binding protein, IGFBP-3. Administered by injection, it’s amazingly versatile; it can:  improve blood sugar levels and reduce insulin use in diabetics, improve muscle rebuilding and reduce inflammation in burns, and improve functional recovery and bone mineral density in hip fractures. SomatoKine(R) is now in Phase III clinical trial to help kids with a severe growth disorder–and results are positive.

Insmed’s website has a page where you can get information on licensing, partnering or developing a research collaboration with them.

China eyes embryo biotechnology

The debate on how to get ahead in bioscience rages.

An article in today’s Chinese People’s Daily Online says scientists are being told to look for the area where they can take the lead. A professor at Connecticut State University, Yang Xiangzhong urged attendees at a conference in Beijing to focus on embryo technology and cloning. He told them that Americans are going slowly in this area because of ethical and religious disapproval and thus their research is done largely with animals, while China has the advantage of being able to conduct human therapeutic cloning.

Oh, and today’s Washington Post announces that proponents of stem cell research are entering the political fight for the White House.

IBM software to aid medical research

IBM has just announced a new software solution that “enables research institutions and biopharmaceutical companies across the world to integrate, store, analyze and better understand genotypic and phenotypic data for medical research and patient care.”

The gist of it is that they capture–and de-identify (a new word for the modern security-conscious HIPAA age)–data from existing hospital and research systems, store data from healthcare institutions and diagnostic labs, then centralize it all to yield the opportunity for research on steroids.

Device entrepreneur seeks connections

Northeast Ohio entrepreneur, Wayne Urban,  has done his homework for a couple of years to get this medical device invention off the ground. This truly home-spun, grassroots effort is introducing a product that fills a real need: a sling that holds up your leg when you’ve been injured and can’t stand on it. Makes a lot of sense to podiatrists.

As founder and CEO of his company, LS Products, LLC, Urban did all the investigative research to learn how to get the FDA approval, the manufacturer producing a prototype, etc. “We have demonstrated it, exhibited at medical tradeshows, been featured on TV, and been written up in newspapers.  We are adding several sales reps, but we feel we need to reach many more people now,” says Urban. 

What better way than to connect through the companies of NEOBio and beyond. Check out their website.

Reducing need for bypass

This is really cool. A new stent that can be put in during angioplasty has been designed to prevent the troubling re-narrowing of arteries that seemed always to happen after the procedure. It’s coated with a drug that prevents the restinosis.

Fewer people living additional healthier years without having to have their chests cut open…that’s what the promise of bioscience is about.

Here's an idea for sharing knowledge

Tomorrow Purdue University is hosting a full-day conference-that’s totally free and open to the public–on how bioscience and nanotechnology can be linked. Speakers from Purdue, Northwestern and U of I will talk about current research and discuss how universities can network on this subject.

Oh, and it’s got some heavy-hitter sponsors: Purdue’s Bindley Bioscience Center, Birck Nanotechnology Center, the Network for Computational Nanotechnology (funded by the National Science Foundation), and the Institute for Nanoelectronics and Computing (funded by NASA).

What've they got?

German biotech supplier Eppendorf chose Connecticut as the place to build a new manufacturing facility. What areas were considered and rejected?

The CEO of Eppendorf, which is based in Hamburg, Germany, gave these reasons for the choice:  “The Enfield site is closer to the company’s markets, has certain unspecified logistical advantages and less exposure to fluctuations in the currency exchange rate.”

Please wait...

Subscribe to our newsletter

Want to be notified when our article is published? Enter your email address and name below to be the first to know.